The Filings Report

Axsome Therapeutics, Inc

AXSMNasdaqCIK 1579428Healthcare / Drug Manufacturersfiscal year ends December47 quarters since 2015

Revenue, Q3 FY2026
$260M
+51.9% on Q3 FY2025
Net income
−$13M
+72.7% on Q3 FY2025
Free cash flow
−$10M
−1078.3% on Q3 FY2025
Diluted EPS
$-0.25
+73.4% on Q3 FY2025
Revenue, TTM
$865M
trailing four quarters
Net margin, TTM
-18.2%
net income −$157M
Free cash flow, TTM
−$83M
−$82M less $839K capex
Cash and equivalents
$314M
long-term debt $118M, Sep 30, 2026
Shares, 12-month change
+4.3%
53M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$7.0B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 2, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Axsome Therapeutics, Inc reported revenue of $260M, +51.9% on Q3 FY2025, and net loss of $13M (+72.7%). Operating margin was −4.3%. Free cash flow, operating cash flow less capital expenditures, was −$10M (−$9M less $197K). Diluted earnings per share were $-0.25.

Share price

Daily candlesticks from November 11, 2024 to November 9, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

AXSM daily priceSplit-adjusted, US dollars; an earnings release
Nov 9, 2026O $133.29 · H $134.71 · L $131.41 · C $133.96 · +1.20% on the dayOver the range: −3.03%, Nov 10, 2025 to Nov 9, 2026
$115$153$192$230$268Nov 25Jan 26Apr 26Jun 26Aug 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of November 2, 2026.

Revenue and net incomeRevenueNet income
−$100M$0$100M$200M$300MQ4'22, Revenue: $24MQ4'22, Net income: −$61MQ4'22Q1'23, Revenue: $95MQ1'23, Net income: −$11MQ1'23Q2'23, Revenue: $47MQ2'23, Net income: −$67MQ2'23Q3'23, Revenue: $58MQ3'23, Net income: −$62MQ3'23Q4'23, Revenue: $72MQ4'23, Net income: −$99MQ4'23Q1'24, Revenue: $75MQ1'24, Net income: −$68MQ1'24Q2'24, Revenue: $87MQ2'24, Net income: −$79MQ2'24Q3'24, Revenue: $105MQ3'24, Net income: −$65MQ3'24Q4'24, Revenue: $119MQ4'24, Net income: −$75MQ4'24Q1'25, Revenue: $121MQ1'25, Net income: −$59MQ1'25Q2'25, Revenue: $150MQ2'25, Net income: −$48MQ2'25Q3'25, Revenue: $171MQ3'25, Net income: −$47MQ3'25Q4'25, Revenue: $196MQ4'25, Net income: −$29MQ4'25Q1'26, Revenue: $191MQ1'26, Net income: −$65MQ1'26Q2'26, Revenue: $218MQ2'26, Net income: −$51MQ2'26Q3'26, Revenue: $260MQ3'26, Net income: −$13MQ3'26−$100M$0$100M$200M$300MQ4'22, Revenue: $24MQ4'22, Net income: −$61MQ4'22Q1'23, Revenue: $95MQ1'23, Net income: −$11MQ1'23Q2'23, Revenue: $47MQ2'23, Net income: −$67MQ2'23Q3'23, Revenue: $58MQ3'23, Net income: −$62MQ3'23Q4'23, Revenue: $72MQ4'23, Net income: −$99MQ4'23Q1'24, Revenue: $75MQ1'24, Net income: −$68MQ1'24Q2'24, Revenue: $87MQ2'24, Net income: −$79MQ2'24Q3'24, Revenue: $105MQ3'24, Net income: −$65MQ3'24Q4'24, Revenue: $119MQ4'24, Net income: −$75MQ4'24Q1'25, Revenue: $121MQ1'25, Net income: −$59MQ1'25Q2'25, Revenue: $150MQ2'25, Net income: −$48MQ2'25Q3'25, Revenue: $171MQ3'25, Net income: −$47MQ3'25Q4'25, Revenue: $196MQ4'25, Net income: −$29MQ4'25Q1'26, Revenue: $191MQ1'26, Net income: −$65MQ1'26Q2'26, Revenue: $218MQ2'26, Net income: −$51MQ2'26Q3'26, Revenue: $260MQ3'26, Net income: −$13MQ3'26−$100M$0$100M$200M$300MQ4'22, Revenue: $24MQ4'22, Net income: −$61MQ1'23, Revenue: $95MQ1'23, Net income: −$11MQ1'23Q2'23, Revenue: $47MQ2'23, Net income: −$67MQ3'23, Revenue: $58MQ3'23, Net income: −$62MQ3'23Q4'23, Revenue: $72MQ4'23, Net income: −$99MQ1'24, Revenue: $75MQ1'24, Net income: −$68MQ1'24Q2'24, Revenue: $87MQ2'24, Net income: −$79MQ3'24, Revenue: $105MQ3'24, Net income: −$65MQ3'24Q4'24, Revenue: $119MQ4'24, Net income: −$75MQ1'25, Revenue: $121MQ1'25, Net income: −$59MQ1'25Q2'25, Revenue: $150MQ2'25, Net income: −$48MQ3'25, Revenue: $171MQ3'25, Net income: −$47MQ3'25Q4'25, Revenue: $196MQ4'25, Net income: −$29MQ1'26, Revenue: $191MQ1'26, Net income: −$65MQ1'26Q2'26, Revenue: $218MQ2'26, Net income: −$51MQ3'26, Revenue: $260MQ3'26, Net income: −$13MQ3'26

Net income losses drawn in red.

Free cash flow
−$60M−$40M−$20M$0$20MQ4'22, Free cash flow: −$28MQ4'22Q1'23, Free cash flow: −$6MQ1'23Q2'23, Free cash flow: −$55MQ2'23Q3'23, Free cash flow: −$54MQ3'23Q4'23, Free cash flow: −$30MQ4'23Q1'24, Free cash flow: −$54MQ1'24Q2'24, Free cash flow: −$30MQ2'24Q3'24, Free cash flow: −$19MQ3'24Q4'24, Free cash flow: −$26MQ4'24Q1'25, Free cash flow: −$44MQ1'25Q2'25, Free cash flow: −$32MQ2'25Q3'25, Free cash flow: $988KQ3'25Q4'25, Free cash flow: −$19MQ4'25Q1'26, Free cash flow: −$21MQ1'26Q2'26, Free cash flow: −$33MQ2'26Q3'26, Free cash flow: −$10MQ3'26−$60M−$40M−$20M$0$20MQ4'22, Free cash flow: −$28MQ4'22Q1'23, Free cash flow: −$6MQ1'23Q2'23, Free cash flow: −$55MQ2'23Q3'23, Free cash flow: −$54MQ3'23Q4'23, Free cash flow: −$30MQ4'23Q1'24, Free cash flow: −$54MQ1'24Q2'24, Free cash flow: −$30MQ2'24Q3'24, Free cash flow: −$19MQ3'24Q4'24, Free cash flow: −$26MQ4'24Q1'25, Free cash flow: −$44MQ1'25Q2'25, Free cash flow: −$32MQ2'25Q3'25, Free cash flow: $988KQ3'25Q4'25, Free cash flow: −$19MQ4'25Q1'26, Free cash flow: −$21MQ1'26Q2'26, Free cash flow: −$33MQ2'26Q3'26, Free cash flow: −$10MQ3'26−$60M−$40M−$20M$0$20MQ4'22, Free cash flow: −$28MQ1'23, Free cash flow: −$6MQ1'23Q2'23, Free cash flow: −$55MQ3'23, Free cash flow: −$54MQ3'23Q4'23, Free cash flow: −$30MQ1'24, Free cash flow: −$54MQ1'24Q2'24, Free cash flow: −$30MQ3'24, Free cash flow: −$19MQ3'24Q4'24, Free cash flow: −$26MQ1'25, Free cash flow: −$44MQ1'25Q2'25, Free cash flow: −$32MQ3'25, Free cash flow: $988KQ3'25Q4'25, Free cash flow: −$19MQ1'26, Free cash flow: −$21MQ1'26Q2'26, Free cash flow: −$33MQ3'26, Free cash flow: −$10MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$200M$400M$600MQ4'22, Cash and equivalents: $201MQ4'22, Long-term debt: $94MQ4'22Q1'23, Cash and equivalents: $247MQ1'23, Long-term debt: $148MQ1'23Q2'23, Cash and equivalents: $437MQ2'23, Long-term debt: $177MQ2'23Q3'23, Cash and equivalents: $417MQ3'23, Long-term debt: $177MQ3'23Q4'23, Cash and equivalents: $386MQ4'23, Long-term debt: $178MQ4'23Q1'24, Cash and equivalents: $331MQ1'24, Long-term debt: $179MQ1'24Q2'24, Cash and equivalents: $316MQ2'24, Long-term debt: $179MQ2'24Q3'24, Cash and equivalents: $327MQ3'24, Long-term debt: $180MQ3'24Q4'24, Cash and equivalents: $315MQ4'24, Long-term debt: $181MQ4'24Q1'25, Cash and equivalents: $301MQ1'25, Long-term debt: $181MQ1'25Q2'25, Cash and equivalents: $303MQ2'25, Long-term debt: $118MQ2'25Q3'25, Cash and equivalents: $325MQ3'25, Long-term debt: $118MQ3'25Q4'25, Cash and equivalents: $323MQ4'25, Long-term debt: $118MQ4'25Q1'26, Cash and equivalents: $305MQ1'26, Long-term debt: $118MQ1'26Q2'26, Cash and equivalents: $320MQ2'26, Long-term debt: $118MQ2'26Q3'26, Cash and equivalents: $314MQ3'26, Long-term debt: $118MQ3'26$0$200M$400M$600MQ4'22, Cash and equivalents: $201MQ4'22, Long-term debt: $94MQ4'22Q1'23, Cash and equivalents: $247MQ1'23, Long-term debt: $148MQ1'23Q2'23, Cash and equivalents: $437MQ2'23, Long-term debt: $177MQ2'23Q3'23, Cash and equivalents: $417MQ3'23, Long-term debt: $177MQ3'23Q4'23, Cash and equivalents: $386MQ4'23, Long-term debt: $178MQ4'23Q1'24, Cash and equivalents: $331MQ1'24, Long-term debt: $179MQ1'24Q2'24, Cash and equivalents: $316MQ2'24, Long-term debt: $179MQ2'24Q3'24, Cash and equivalents: $327MQ3'24, Long-term debt: $180MQ3'24Q4'24, Cash and equivalents: $315MQ4'24, Long-term debt: $181MQ4'24Q1'25, Cash and equivalents: $301MQ1'25, Long-term debt: $181MQ1'25Q2'25, Cash and equivalents: $303MQ2'25, Long-term debt: $118MQ2'25Q3'25, Cash and equivalents: $325MQ3'25, Long-term debt: $118MQ3'25Q4'25, Cash and equivalents: $323MQ4'25, Long-term debt: $118MQ4'25Q1'26, Cash and equivalents: $305MQ1'26, Long-term debt: $118MQ1'26Q2'26, Cash and equivalents: $320MQ2'26, Long-term debt: $118MQ2'26Q3'26, Cash and equivalents: $314MQ3'26, Long-term debt: $118MQ3'26$0$200M$400M$600MQ4'22, Cash and equivalents: $201MQ4'22, Long-term debt: $94MQ1'23, Cash and equivalents: $247MQ1'23, Long-term debt: $148MQ1'23Q2'23, Cash and equivalents: $437MQ2'23, Long-term debt: $177MQ3'23, Cash and equivalents: $417MQ3'23, Long-term debt: $177MQ3'23Q4'23, Cash and equivalents: $386MQ4'23, Long-term debt: $178MQ1'24, Cash and equivalents: $331MQ1'24, Long-term debt: $179MQ1'24Q2'24, Cash and equivalents: $316MQ2'24, Long-term debt: $179MQ3'24, Cash and equivalents: $327MQ3'24, Long-term debt: $180MQ3'24Q4'24, Cash and equivalents: $315MQ4'24, Long-term debt: $181MQ1'25, Cash and equivalents: $301MQ1'25, Long-term debt: $181MQ1'25Q2'25, Cash and equivalents: $303MQ2'25, Long-term debt: $118MQ3'25, Cash and equivalents: $325MQ3'25, Long-term debt: $118MQ3'25Q4'25, Cash and equivalents: $323MQ4'25, Long-term debt: $118MQ1'26, Cash and equivalents: $305MQ1'26, Long-term debt: $118MQ1'26Q2'26, Cash and equivalents: $320MQ2'26, Long-term debt: $118MQ3'26, Cash and equivalents: $314MQ3'26, Long-term debt: $118MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 2, 2026.

Axsome Therapeutics, Inc income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 2, 2026Q2 FY2026ended Jun 30, 2026filed Aug 10, 2026Q1 FY2026ended Mar 31, 2026filed May 4, 2026Q4 FY2025ended Dec 31, 2025filed Feb 23, 2026Q3 FY2025ended Sep 30, 2025filed Nov 3, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 5, 2025Q4 FY2024ended Dec 31, 2024filed Feb 18, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue260218191196171150121119+51.9%
Cost of revenue—————————
Gross profit—————————
Research and development5146534940504555+26.0%
Selling, general and administrative203208185169150130121113+35.2%
Operating income(11)(50)(63)(27)(46)(37)(57)(73)+76.0%
Other income (expense)—————————
Pretax income(13)(51)(65)(28)(47)(49)(59)(75)+72.9%
Income tax00000(1)00—
Net income(13)(51)(65)(29)(47)(48)(59)(75)+72.7%
Diluted EPS ($)(0.25)(0.99)(1.26)—(0.94)(0.97)(1.22)—+73.4%
Diluted shares (millions)525251—504949——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 2, 2026.

Axsome Therapeutics, Inc balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 2, 2026Q2 FY2026ended Jun 30, 2026filed Aug 10, 2026Q1 FY2026ended Mar 31, 2026filed May 4, 2026Q4 FY2025ended Dec 31, 2025filed Feb 23, 2026Q3 FY2025ended Sep 30, 2025filed Nov 3, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 5, 2025Q4 FY2024ended Dec 31, 2024filed Feb 18, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents314320305323325303301315−3.5%
Short-term investments—————————
Total current assets725657611589565537495485+28.2%
Total assets827761714690669640597568+23.5%
Total current liabilities510460439379360342244230+41.5%
Long-term debt118118118118118118181181+0.4%
Total liabilities721678659602596567543511+21.1%
Stockholders’ equity10583558874735357+43.0%
Shares outstanding (millions)5352515150504949—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 2, 2026.

Axsome Therapeutics, Inc cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 2, 2026Q2 FY2026ended Jun 30, 2026filed Aug 10, 2026Q1 FY2026ended Mar 31, 2026filed May 4, 2026Q4 FY2025ended Dec 31, 2025filed Feb 23, 2026Q3 FY2025ended Sep 30, 2025filed Nov 3, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 5, 2025Q4 FY2024ended Dec 31, 2024filed Feb 18, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow(9)(33)(21)(19)1(32)(43)(26)−1005.3%
Capital expenditures00000000+239.7%
Free cash flow (CFO − capex)(10)(33)(21)(19)1(32)(44)(26)−1078.3%
Depreciation and amortization—————————
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 23, 2026.

Income statement

Axsome Therapeutics, Inc income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 23, 2026FY2024ended Dec 31, 2024filed Feb 18, 2025FY2023ended Dec 31, 2023filed Feb 23, 2024FY2022ended Dec 31, 2022filed Feb 28, 2023FY2021ended Dec 31, 2021filed Mar 1, 2022FY2020ended Dec 31, 2020filed Mar 1, 2021FY2019ended Dec 31, 2019filed Mar 12, 2020FY2018ended Dec 31, 2018filed Mar 15, 2019FY2017ended Dec 31, 2017filed Mar 7, 2018FY2016ended Dec 31, 2016filed Mar 7, 2017FY2015ended Dec 31, 2015filed May 11, 2016FY2014ended Dec 31, 2014filed Mar 7, 2017
Revenue63838627150————————
Cost of revenue———5————————
Gross profit————————————
Research and development183187985858705423202174
Selling, general and administrative57141132315967291497621
Operating income(167)(281)(232)(180)(125)(99)(67)(33)(27)(28)(9)(6)
Other income (expense)————————————
Pretax income(184)(287)(238)(187)(130)———————
Income tax(1)010000000——
Net income(183)(287)(239)(187)(130)(103)(68)(31)(29)(27)(12)(6)
Diluted EPS ($)(3.68)(5.99)(5.27)(4.60)(3.47)(2.77)——————
Diluted shares (millions)504845413837——————

Balance sheet

Axsome Therapeutics, Inc balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 23, 2026FY2024ended Dec 31, 2024filed Feb 18, 2025FY2023ended Dec 31, 2023filed Feb 23, 2024FY2022ended Dec 31, 2022filed Feb 28, 2023FY2021ended Dec 31, 2021filed Mar 1, 2022FY2020ended Dec 31, 2020filed Mar 1, 2021FY2019ended Dec 31, 2019filed Mar 12, 2020FY2018ended Dec 31, 2018filed Mar 15, 2019FY2017ended Dec 31, 2017filed Mar 7, 2018FY2016ended Dec 31, 2016filed Mar 7, 2017FY2015ended Dec 31, 2015filed May 11, 2016FY2014ended Dec 31, 2014filed Mar 7, 2017
Cash and equivalents32331538620186184220—————
Short-term investments————————————
Total current assets5894855042468718422015353849—
Total assets6905685883318818622115363849—
Total current liabilities37923013997232324111273—
Long-term debt11818117894494817479——
Total liabilities6025113972227272421419173—
Stockholders’ equity8857191110161141791172246(3)
Shares outstanding (millions)51494744383737332519——

Cash flow statement

Axsome Therapeutics, Inc cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 23, 2026FY2024ended Dec 31, 2024filed Feb 18, 2025FY2023ended Dec 31, 2023filed Feb 23, 2024FY2022ended Dec 31, 2022filed Feb 28, 2023FY2021ended Dec 31, 2021filed Mar 1, 2022FY2020ended Dec 31, 2020filed Mar 1, 2021FY2019ended Dec 31, 2019filed Mar 12, 2020FY2018ended Dec 31, 2018filed Mar 15, 2019FY2017ended Dec 31, 2017filed Mar 7, 2018FY2016ended Dec 31, 2016filed Mar 7, 2017FY2015ended Dec 31, 2015filed May 11, 2016FY2014ended Dec 31, 2014filed Mar 7, 2017
Operating cash flow(93)(128)(145)(117)(108)(78)(46)(30)(26)(21)(7)(5)
Capital expenditures00110000000—
Free cash flow (CFO − capex)(94)(129)(146)(117)(109)(79)(46)(30)(26)(21)(7)—
Depreciation and amortization————————————
Share repurchases————————————
Dividends paid————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 9, 2024 to November 9, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$2M
1 sales by 1 insider; officers and directors $2M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$113M
30 sales by 8 insiders; officers and directors $113M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 3, 2026Jacobson Mark L.Chief Operating Officeroption exercise10,000$12.95$130K10,000Sep 3, 2026
Sep 3, 2026Jacobson Mark L.Chief Operating Officeropen-market sale10b5-110,000$208.65$2M0Sep 3, 2026
Aug 6, 2026Tabuteau HerriotChief Executive Officer, Director, 10% owneroption exercise4,660$4.95$23K11,889Aug 7, 2026
Aug 6, 2026Tabuteau HerriotChief Executive Officer, Director, 10% owneropen-market sale10b5-14,660$213.95$997K7,229Aug 7, 2026
Aug 5, 2026Tabuteau HerriotChief Executive Officer, Director, 10% owneroption exercise45,004$4.95$223K52,233Aug 7, 2026
Aug 5, 2026Tabuteau HerriotChief Executive Officer, Director, 10% owneropen-market sale10b5-145,004$212.01$10M7,229Aug 7, 2026
Jul 1, 2026Tabuteau HerriotChief Executive Officer, Director, 10% owneroption exercise49,666$4.95$246K56,895Jul 1, 2026
Jul 1, 2026Tabuteau HerriotChief Executive Officer, Director, 10% owneropen-market sale10b5-149,666$240.25$12M7,229Jul 1, 2026
Jun 11, 2026Jeffs RogerDirectoropen-market sale10b5-1286$249.12$71K58,367Jun 11, 2026
Jun 10, 2026Jeffs RogerDirectoropen-market sale10b5-1286$246.18$70K58,653Jun 11, 2026
Jun 10, 2026Mahony SusanDirectoropen-market sale10b5-1300$246.18$74K829Jun 10, 2026
Jun 10, 2026Coleman MarkDirectoropen-market sale10b5-1643$249.00$160K30,389Jun 10, 2026
Jun 9, 2026Mahony SusanDirectoropen-market sale10b5-1300$237.21$71K1,129Jun 10, 2026
Jun 9, 2026Tabuteau HerriotChief Executive Officer, Director, 10% owneroption exercise49,670$4.95$246K56,899Jun 9, 2026
Jun 9, 2026Tabuteau HerriotChief Executive Officer, Director, 10% owneropen-market sale10b5-149,670$241.01$12M7,229Jun 9, 2026
Jun 9, 2026Pizzie NickChief Financial Officeroption exercise33,000$3.50$116K75,867Jun 9, 2026
Jun 9, 2026Pizzie NickChief Financial Officeropen-market sale10b5-133,000$240.09$8M42,867Jun 9, 2026
Jun 8, 2026Jeffs RogerDirectoroption exercise1,429——58,939Jun 10, 2026
Jun 8, 2026Saad Mark EDirectoroption exercise1,429——11,431Jun 10, 2026
Jun 8, 2026Mahony SusanDirectoroption exercise1,429——1,429Jun 10, 2026
Jun 8, 2026Coleman MarkDirectoroption exercise1,429——31,032Jun 10, 2026
Jun 2, 2026Coleman MarkDirectoropen-market sale10b5-15,537$223.39$1M29,603Jun 2, 2026
Jun 1, 2026Coleman MarkDirectoropen-market sale10b5-16,000$230.30$1M35,140Jun 2, 2026
May 29, 2026Coleman MarkDirectoropen-market sale10b5-16,000$233.46$1M41,140Jun 2, 2026
May 5, 2026Jacobson Mark L.Chief Operating Officeroption exercise233$12.95$3K233May 5, 2026

Full insider history for Axsome Therapeutics, Inc, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held AXSM in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded AXSM by quarter.

FundManagerQuarterValueSharesWeightMove
Baron Capital GroupRon BaronQ2 2026$734K3,0000.00%new

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
AXSOME THERAPEUTICS, INC., CIK 1579428 on EDGAR
Extract generated
November 8, 2026
Withheld
4 line-years whose four quarters do not sum to the filed year: operating income FY2015, operating income FY2016, operating income FY2017, operating income FY2018
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfRevenue
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense, SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): not filed
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: not filed
Share repurchases: not filed
Dividends paid: not filed

The data

The statements on this page as files, generated November 8, 2026.

JSON file
/data/financials/AXSM.json